Spyre Therapeutics, Inc. Common Stock (SYRE)
Spyre Therapeutics, Inc. (SYRE) is a biotechnology company focused on developing targeted therapies for immune-mediated diseases. The company leverages its proprietary technology platform to discover and advance novel biologics aimed at modulating immune responses, with the goal of treating conditions such as autoimmune disorders and inflammatory diseases.
Company News
Spyre Therapeutics presented interim Phase 1 results for SPY002, an anti-TL1A antibody for IBD, showing promising dosing potential and preclinical data supporting combination therapy efficacy.
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. (NYSE: NIO) rose during Tuesday’s session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter. Analysts, on...
Spyre Therapeutics (SYRE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.